Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Hodgkin Disease 33Lymphoma 17Lymphoma, Large-Cell, Anaplastic 15Hematologic Diseases 13Lymphoma, Non-Hodgkin 10Recurrence 9Lymphoma, T-Cell 7Lymphoma, T-Cell, Peripheral 6Lymphoma, Large B-Cell, Diffuse 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, B-Cell 4Neoplasms 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphatic Diseases 3Leukemia 3Immunoblastic Lymphadenopathy 3Sezary Syndrome 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Germ Cell and Embryonal 2Neoplasms by Histologic Type 2Lymphoproliferative Disorders 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Myeloid, Acute 2Immunoproliferative Disorders 2Immune System Diseases 2Enteropathy-Associated T-Cell Lymphoma 2Waldenstrom Macroglobulinemia 1Testicular Neoplasms 1Nonseminomatous germ cell tumor 1

Interventions

blinatumomab 4Rituximab 4Cyclophosphamide 3ponatinib 2Vorinostat 2Vincristine 2Prednisone 2Ifosfamide 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2Bortezomib 2tetulomab tetraxetan lu-177 1pembrolizumab 1pegaspargase 1ibrutinib 1ibritumomab tiuxetan 1durvalumab 1cobomarsen 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Methotrexate 1Melphalan 1Lutetium 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Hsp90 inhibitor KU757 1Dexamethasone 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Immunoproliferative Disorders × Brentuximab Vedotin × Clear all
NCT01990534 2021-04-09

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Takeda

Phase 4 Completed
60 enrolled 21 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡